Moteur de recherche d’entreprises européennes
Financement de l’UE (4 021 969 €) : Innovation en pharmacologie de sécurité pour l’évaluation intégrée de la sécurité cardiovasculaire afin de réduire les événements indésirables et l’attrition des … Hor28/08/2019 Programme de recherche et d'innovation de l'UE « Horizon »
Vue d’ensemble
Texte
Innovation en pharmacologie de sécurité pour l’évaluation intégrée de la sécurité cardiovasculaire afin de réduire les événements indésirables et l’attrition des médicaments à un stade avancé.
New drug candidates often have off-target effects resulting in adverse events, thus representing a major limitation for drug R&D. Safety Pharmacology (SP) aims to detect, understand and reduce undesirable pharmacodynamic effects early-on. Especially, cardiovascular (CV) toxicity is problematic, as it is the most prevalent reason for failure during preclinical development. Moreover, CV toxicity remains a key reason for drug attrition during clinical development and beyond. This indicates current SP screens fail to detect a number of (late-onset) functional or structural CV toxicities. Additionally, SP uses a significant number of laboratory animals, thereby creating opportunities for a better implementation of the 3Rs. The vision of INSPIRE is to advance and “inspire” SP by exploring new technological capabilities (WP1), addressing emerging CV concerns (WP2) and delivering new validated solutions for CV safety screening (WP3). To this end, INSPIRE unites expertise from academic teams, technology-providers, pharmaceutical companies, regulators and hospitals to create a European training platform for 15 Early Stage Researchers (ESRs). Key innovative aspects of INSPIRE include: i) in vitro humanized cardiomyocytes assays, ii) unparalleled in vivo hardware/software solutions, iii) in silico predictions of haemodynamics, iv) mass spectroscopy imaging of drug exposure, v) exploration of mechanisms of late-onset CV toxicity, as observed in cardio-oncology, and vi) early integration of feedback from industry and regulators. Overall, INSPIRE constitutes a multidisciplinary and intersectoral training programme (WP4) with a balanced combination of hands-on research training, intersectoral secondments, local courses and network-wide events on scientific and transferable skills, enabling future R&I collaborations. Hence, INSPIRE will equip the future generation of SP scientists with a wide range of scientific knowledge and the ability to adapt to a dynamic ever-changing industry.
| Boehringer Ingelheim Pharma GmbH & Co. KG | 252 788 € |
| Institut National de Recherche en Informatique et Automatique | 274 802 € |
| Ncardia B.V. | 0,00 € |
| Ncardia Services B.V. | 265 620 € |
| Notocord Systems | 549 604 € |
| The University of Nottingham | 606 345 € |
| TSE Systems GmbH | 252 788 € |
| UCB Biopharma | 256 320 € |
| Universiteit Antwerpen | 768 960 € |
| Universiteit Maastricht | 531 240 € |
| Weizmann Institute OF Science | 263 501 € |
https://cordis.europa.eu/project/id/858070
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.